$REVB
REVELATION BIOSCIENCES, INC.

2023 Q3 Form 10-Q Financial Statement

#000095017023041851 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.130M $1.024M
YoY Change 38.16% 15.7%
% of Gross Profit
Research & Development $1.651M $909.3K
YoY Change 332.79% -6.8%
% of Gross Profit
Depreciation & Amortization $6.262K $6.262K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $2.778M $1.933M
YoY Change 131.59% 3.9%
Operating Profit -$2.778M -$1.933M
YoY Change 131.59% 3.9%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $149.5K $484.9K
YoY Change 420.47% 1784.12%
Pretax Income -$2.630M -$1.448M
YoY Change 124.64% -21.07%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.628M -$1.448M
YoY Change 124.51% -21.07%
Net Earnings / Revenue
Basic Earnings Per Share -$0.42 -$0.25
Diluted Earnings Per Share -$0.42 -$0.25
COMMON SHARES
Basic Shares Outstanding 6.297M 6.049M
Diluted Shares Outstanding 6.297M 5.812M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.99M $15.71M
YoY Change 125.81% 352.01%
Cash & Equivalents $14.00M $15.70M
Short-Term Investments
Other Short-Term Assets $150.0K $250.0K
YoY Change -51.56% -56.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.15M $15.96M
YoY Change 117.48% 293.98%
LONG-TERM ASSETS
Property, Plant & Equipment $71.35K $77.61K
YoY Change -25.99% -24.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $71.35K $77.61K
YoY Change -25.99% -24.4%
TOTAL ASSETS
Total Short-Term Assets $14.15M $15.96M
Total Long-Term Assets $71.35K $77.61K
Total Assets $14.22M $16.04M
YoY Change 115.38% 286.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.257M $913.9K
YoY Change 169.74% -0.28%
Accrued Expenses $1.022M $496.9K
YoY Change -36.12% -77.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.400M $4.624M
YoY Change 23.46% -22.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.400M $4.624M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $5.400M $4.624M
YoY Change 23.46% -22.89%
SHAREHOLDERS EQUITY
Retained Earnings -$23.30M -$20.60M
YoY Change -3.32% -10.43%
Common Stock $6.297K $6.297K
YoY Change -73.25% -58.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.800M $11.40M
YoY Change
Total Liabilities & Shareholders Equity $14.22M $16.04M
YoY Change 115.38% 286.11%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$2.628M -$1.448M
YoY Change 124.51% -21.07%
Depreciation, Depletion And Amortization $6.262K $6.262K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$1.710M -$1.992M
YoY Change -1.24% -46.32%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 20.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.710M -1.992M
Cash From Investing Activities
Cash From Financing Activities 0.000 20.00
Net Change In Cash -1.710M -1.992M
YoY Change -162.88% -46.32%
FREE CASH FLOW
Cash From Operating Activities -$1.710M -$1.992M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001810560
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.03
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.03
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.03
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39603
dei Entity Registrant Name
EntityRegistrantName
REVELATION BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3898466
dei Entity Address Address Line1
EntityAddressAddressLine1
4660 La Jolla Village Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
800-3717
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
REVB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6297303
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15711218
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5252979
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
87171
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
250012
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
73132
CY2023Q2 us-gaap Assets Current
AssetsCurrent
15961230
CY2022Q4 us-gaap Assets Current
AssetsCurrent
5413282
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
77608
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90133
CY2023Q2 us-gaap Assets
Assets
16038838
CY2022Q4 us-gaap Assets
Assets
5503415
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
913866
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
554205
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
496870
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
985497
CY2023Q2 revb Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2911260
CY2022Q4 revb Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2911260
CY2023Q2 revb Warrant Liability
WarrantLiability
302039
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4624035
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4450962
CY2023Q2 us-gaap Liabilities
Liabilities
4624035
CY2022Q4 us-gaap Liabilities
Liabilities
4450962
us-gaap Net Income Loss
NetIncomeLoss
-8451227
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.16
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
11000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6297303
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6297303
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
682882
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
682882
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6297
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
683
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32044329
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26398618
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20635823
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25346848
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11414803
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1052453
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16038838
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5503415
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
909278
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
975583
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1434551
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4655863
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1023752
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
884837
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2118326
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3790857
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1933030
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
1860420
us-gaap Operating Expenses
OperatingExpenses
3552877
us-gaap Operating Expenses
OperatingExpenses
8446720
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1933030
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1860420
us-gaap Operating Income Loss
OperatingIncomeLoss
-3552877
us-gaap Operating Income Loss
OperatingIncomeLoss
-8446720
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-423239
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8168174
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
61621
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25734
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
95728
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4507
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
484860
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25734
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8263902
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4507
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1448170
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1834686
us-gaap Net Income Loss
NetIncomeLoss
4711025
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-19.71
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5812278
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
441351
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2922195
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
428837
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-19.71
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5812278
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
441351
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3072695
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
428837
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-99470
CY2022Q1 revb Issuance Of Common Stock In Connection With The Business Combination Net
IssuanceOfCommonStockInConnectionWithTheBusinessCombinationNet
6864327
CY2022Q1 revb Issuance Of Common Stock For Fees In Connection With Business Combination
IssuanceOfCommonStockForFeesInConnectionWithBusinessCombination
300
CY2022Q1 revb Proceeds From Pipe Investment Net
ProceedsFromPipeInvestmentNet
7262219
CY2022Q1 revb Rollover Warrant Exercise
RolloverWarrantExercise
5074
CY2022Q1 revb Repurchase For The Forward Share Purchase Agreement Exercise
RepurchaseForTheForwardSharePurchaseAgreementExercise
7652325
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
137892
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6616541
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-98511
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
90188
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1834686
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1843009
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1052453
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32095
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
6159195
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10017646
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
59435
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1448170
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11414803
us-gaap Net Income Loss
NetIncomeLoss
4711025
us-gaap Net Income Loss
NetIncomeLoss
-8451227
us-gaap Share Based Compensation
ShareBasedCompensation
91530
us-gaap Share Based Compensation
ShareBasedCompensation
228080
us-gaap Depreciation
Depreciation
12525
us-gaap Depreciation
Depreciation
12524
revb Non Cash Lease Expense
NonCashLeaseExpense
0
revb Non Cash Lease Expense
NonCashLeaseExpense
14960
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8168174
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
176880
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-66695
revb Increase Decrease In Deferred Offering Costs
IncreaseDecreaseInDeferredOfferingCosts
-61154
revb Increase Decrease In Deferred Offering Costs
IncreaseDecreaseInDeferredOfferingCosts
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
377578
revb Units Separated Into Common Stock And Public Warrant Description
UnitsSeparatedIntoCommonStockAndPublicWarrantDescription
On January 13, 2023, the Company’s units were mandatorily separated into one share of common stock and one Public Warrant and ceased trading on the Nasdaq Capital Market (see Note 9).
CY2023Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
35
CY2023Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20600000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11400000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15700000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-285855
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-475527
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-145856
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-16752
revb Increase Decrease In Accrued Interest Notes Payable And Convertible Note
IncreaseDecreaseInAccruedInterestNotesPayableAndConvertibleNote
0
revb Increase Decrease In Accrued Interest Notes Payable And Convertible Note
IncreaseDecreaseInAccruedInterestNotesPayableAndConvertibleNote
36920
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3566769
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8540511
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2500000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2500000
revb Proceeds From Business Combination Financing Activity
ProceedsFromBusinessCombinationFinancingActivity
0
revb Proceeds From Business Combination Financing Activity
ProceedsFromBusinessCombinationFinancingActivity
11923499
revb Proceeds From Pipe Investment Financing Activity
ProceedsFromPipeInvestmentFinancingActivity
0
revb Proceeds From Pipe Investment Financing Activity
ProceedsFromPipeInvestmentFinancingActivity
7262219
revb Repurchase For The Forward Share Purchase Agreement Exercise
RepurchaseForTheForwardSharePurchaseAgreementExercise
0
revb Repurchase For The Forward Share Purchase Agreement Exercise
RepurchaseForTheForwardSharePurchaseAgreementExercise
7652325
revb Repayments Of Notes Payable Including Interest
RepaymentsOfNotesPayableIncludingInterest
0
revb Repayments Of Notes Payable Including Interest
RepaymentsOfNotesPayableIncludingInterest
796882
us-gaap Payments For Repurchase Of Redeemable Preferred Stock
PaymentsForRepurchaseOfRedeemablePreferredStock
5000
us-gaap Payments For Repurchase Of Redeemable Preferred Stock
PaymentsForRepurchaseOfRedeemablePreferredStock
0
revb Proceeds From Public Offering Net
ProceedsFromPublicOfferingNet
14029974
revb Proceeds From Public Offering Net
ProceedsFromPublicOfferingNet
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14025008
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10741598
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
10458239
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2201087
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5252979
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1274729
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15711218
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3475816
revb Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
-26017
revb Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
0
revb Alternative Cashless Of Common Stock Warrants Exercise
AlternativeCashlessOfCommonStockWarrantsExercise
5526287
revb Alternative Cashless Of Common Stock Warrants Exercise
AlternativeCashlessOfCommonStockWarrantsExercise
0
revb Noncash Or Part Non Cash Acquisition Current Liabilities Assumed
NoncashOrPartNonCashAcquisitionCurrentLiabilitiesAssumed
0
revb Noncash Or Part Non Cash Acquisition Current Liabilities Assumed
NoncashOrPartNonCashAcquisitionCurrentLiabilitiesAssumed
2149432
revb Deferred Underwriting Commissions Assumed In Business Combination
DeferredUnderwritingCommissionsAssumedInBusinessCombination
0
revb Deferred Underwriting Commissions Assumed In Business Combination
DeferredUnderwritingCommissionsAssumedInBusinessCombination
2911260
revb Noncash Equity Issuance For Fees Upon Business Combination
NoncashEquityIssuanceForFeesUponBusinessCombination
0
revb Noncash Equity Issuance For Fees Upon Business Combination
NoncashEquityIssuanceForFeesUponBusinessCombination
300
revb Noncash Issuance Of Common Warrants Pipe Investment
NoncashIssuanceOfCommonWarrantsPipeInvestment
0
revb Noncash Issuance Of Common Warrants Pipe Investment
NoncashIssuanceOfCommonWarrantsPipeInvestment
3634262
revb Noncash Issuance Of Placement Agent Warrants With Pipe Investment
NoncashIssuanceOfPlacementAgentWarrantsWithPipeInvestment
0
revb Noncash Issuance Of Placement Agent Warrants With Pipe Investment
NoncashIssuanceOfPlacementAgentWarrantsWithPipeInvestment
508797
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. These estimates and assumptions are based on the Company’s best estimates and judgment. The Company regularly evaluates its estimates and assumptions using historical and industry experience and other factors; however, actual results could differ materially from these estimates and could have an adverse effect on the Company’s condensed consolidated financial statements.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Bank deposits are held by accredited financial institutions and these deposits may at times be in excess of federally insured limits. The Company limits its credit risk associated with cash and cash equivalents by placing them with financial institutions that it believes are of high quality. The Company has not experienced any losses on its deposits of cash or cash equivalents.</span></p>
us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1169255
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
150500
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
412594
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
412594
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 revb Prepaid Clinical Costs Current
PrepaidClinicalCostsCurrent
142500
CY2023Q2 revb Other Prepaid Expense And Current Assets
OtherPrepaidExpenseAndCurrentAssets
107512
CY2022Q4 revb Other Prepaid Expense And Current Assets
OtherPrepaidExpenseAndCurrentAssets
73132
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
250012
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
73132
CY2023Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
131963
CY2022Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
131963
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
131963
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
131963
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
54355
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
41830
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
77608
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90133
CY2023Q2 us-gaap Depreciation
Depreciation
6262
us-gaap Depreciation
Depreciation
12525
CY2022Q2 us-gaap Depreciation
Depreciation
6262
us-gaap Depreciation
Depreciation
12524
CY2023Q2 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
329453
CY2022Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
618014
CY2022Q4 revb Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
175061
CY2023Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
99117
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
75722
CY2023Q2 revb Accrued Clinical Development Costs
AccruedClinicalDevelopmentCosts
68300
CY2022Q4 revb Accrued Clinical Development Costs
AccruedClinicalDevelopmentCosts
111700
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
5000
CY2023Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
496870
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
985497
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
5000
CY2023Q1 revb Lessee Operating Lease Liability Base Monthly Rent
LesseeOperatingLeaseLiabilityBaseMonthlyRent
9630
CY2021Q1 us-gaap Security Deposit Liability
SecurityDepositLiability
5564
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
28890
us-gaap Operating Lease Expense
OperatingLeaseExpense
53881
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
17193
us-gaap Operating Lease Expense
OperatingLeaseExpense
32260
CY2022Q1 revb Common Stock Transferred
CommonStockTransferred
7001
CY2022Q2 revb Interest Incurred
InterestIncurred
0
revb Interest Incurred
InterestIncurred
14383
CY2022Q1 us-gaap Noninterest Expense Investment Advisory Fees
NoninterestExpenseInvestmentAdvisoryFees
2700000
CY2022Q1 revb Noninterest Expense Investment Advisory Fees In Form Of Equity
NoninterestExpenseInvestmentAdvisoryFeesInFormOfEquity
2600000
CY2022Q1 revb Transaction Expenses
TransactionExpenses
8500000
CY2022Q1 revb Deferred Underwriting Fees
DeferredUnderwritingFees
1500000
CY2022Q1 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
655000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1600000
CY2023Q1 revb Number Of Units Seperation
NumberOfUnitsSeperation
1688598
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
238096
CY2022Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
4500000
CY2022Q3 revb Percentage Of Placement Agent Cash Fee On Gross Proceeds Received
PercentageOfPlacementAgentCashFeeOnGrossProceedsReceived
0.070
CY2022Q3 revb Placement Agent Cash Fee Amount
PlacementAgentCashFeeAmount
350000
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2888600
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
14000000.0
CY2023Q1 revb Percentage Of Placement Agent Cash Fee On Gross Proceeds Received
PercentageOfPlacementAgentCashFeeOnGrossProceedsReceived
0.080
CY2023Q1 revb Placement Agent Cash Fee Amount
PlacementAgentCashFeeAmount
1200000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
revb Class Of Warrant Or Right For Issuing Description
ClassOfWarrantOrRightForIssuingDescription
October of 2020, Petra issued unit's that consisted of one share of common stock and one warrant exercisable for 1/35 of a share of common stock with an exercise price of $402.50 per share which expire on January 10, 2027 (the “Public Warrants”), which traded on the Nasdaq Capital Market under the ticker symbol REVBU.
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
As a result of the Reverse Split, every 35 shares of the Company’s issued and outstanding common stock automatically converted into one share of common stock, without any change in the par value per share. No fractional shares were outstanding following the Reverse Split. Any holder who would have received a fractional share of common stock automatically received an additional fraction of a share of common stock to round up to the next whole share. In addition, effective as of the same time as the Reverse Split, proportionate adjustments were made to all then-outstanding equity awards and warrants with respect to the number of shares of common stock subject to such award or warrant and the exercise price thereof. Furthermore, the number of shares of common stock available for issuance under the Company’s equity incentive plans were proportionately adjusted for the Reverse Split ratio, such that fewer shares will be subject to such plans.
CY2022Q1 us-gaap Proceeds From Previous Acquisition
ProceedsFromPreviousAcquisition
11900000
CY2022Q1 revb Escrowed Amount
EscrowedAmount
7700000
CY2022Q1 revb Released Amount
ReleasedAmount
4200000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6297303
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6297303
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
682882
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
682882
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1202538
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
470764
CY2022Q1 revb Percentage Of Aggregate Number Of Outstanding Shares Of Common Stock
PercentageOfAggregateNumberOfOutstandingSharesOfCommonStock
0.10
revb Weighted Average Black Scholes Value Per Stock Option
WeightedAverageBlackScholesValuePerStockOption
10.47
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59435
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
90188
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91530
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
228080
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 revb Non Taxable Income From Fair Value Change Of Warrant Liability
NonTaxableIncomeFromFairValueChangeOfWarrantLiability
400000
revb Non Taxable Income From Fair Value Change Of Warrant Liability
NonTaxableIncomeFromFairValueChangeOfWarrantLiability
8200000

Files In Submission

Name View Source Status
0000950170-23-041851-index-headers.html Edgar Link pending
0000950170-23-041851-index.html Edgar Link pending
0000950170-23-041851.txt Edgar Link pending
0000950170-23-041851-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
revb-20230630.htm Edgar Link pending
revb-20230630.xsd Edgar Link pending
revb-ex31_1.htm Edgar Link pending
revb-ex31_2.htm Edgar Link pending
revb-ex32_1.htm Edgar Link pending
revb-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
revb-20230630_def.xml Edgar Link unprocessable
revb-20230630_lab.xml Edgar Link unprocessable
revb-20230630_pre.xml Edgar Link unprocessable
revb-20230630_htm.xml Edgar Link completed
revb-20230630_cal.xml Edgar Link unprocessable